Development asset linked to BioMarin Pharmaceutical Australia in public FDA and regional records.
pharma · Phenylketonuria · Achondroplasia
BioMarin Pharmaceutical Australia
BioMarin Pharmaceutical Australia Pty Ltd
BioMarin Pharmaceutical Australia drug portfolio — 36 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
770 Lindaro Street, San Rafael, CA 94901, US HQ
1997 Founded
3,171 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- 770 Lindaro Street, San Rafael, CA 94901, US
- Founded
- 1997
- Employees
- 3,171
- Programs
- 91
- Drugs
- 36
- Patents
- 175
BioMarin Pharmaceutical Australia pipeline
Portfolio lens on 36 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
BioMarin Pharmaceutical Australia drug portfolio — 36 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to BioMarin Pharmaceutical Australia in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Aromatic-L-amino-acid decarboxylase.
- Target
- Aromatic-L-amino-acid decarboxylase
- Mechanism
- DOPA decarboxylase inhibitor
-
cerliponase alfa
Alimentary tract and metabolism (A16)US regulatory status: approved. Molecular target: Polypeptides.
- Target
- Polypeptides
- Mechanism
- Polypeptides proteolytic enzyme
-
Development asset linked to BioMarin Pharmaceutical Australia in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to BioMarin Pharmaceutical Australia in public FDA and regional records.
-
elosulfase alfa
Alimentary tract and metabolism (A16)US regulatory status: approved. Molecular target: Chondroitin-6-sulfate.
- Target
- Chondroitin-6-sulfate
- Mechanism
- Chondroitin-6-sulfate hydrolytic enzyme
-
Development asset linked to BioMarin Pharmaceutical Australia in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Bacterial 70S ribosome.
- Target
- Bacterial 70S ribosome
- Mechanism
- Bacterial 70S ribosome inhibitor
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
galsulfase
Alimentary tract and metabolism (A16)US regulatory status: approved. Molecular target: Dermatan sulfate.
- Target
- Dermatan sulfate
- Mechanism
- Dermatan sulfate hydrolytic enzyme
-
Development asset linked to BioMarin Pharmaceutical Australia in public FDA and regional records.
-
Development asset linked to BioMarin Pharmaceutical Australia in public FDA and regional records.
-
Development asset linked to BioMarin Pharmaceutical Australia in public FDA and regional records.
-
Development asset linked to BioMarin Pharmaceutical Australia in public FDA and regional records.
-
laronidase
Alimentary tract and metabolism (A16)US regulatory status: approved. Molecular target: Dermatan sulfate.
- Target
- Dermatan sulfate
- Mechanism
- Dermatan sulfate hydrolytic enzyme
-
melatonin
Nervous system (N05)Nervous system (N05) compound in BioMarin Pharmaceutical Australia's portfolio. Molecular target: Melatonin receptor.
- Target
- Melatonin receptor
- Mechanism
- Melatonin receptor agonist
-
Development asset linked to BioMarin Pharmaceutical Australia in public FDA and regional records.
-
pegvaliase
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in BioMarin Pharmaceutical Australia's portfolio. Molecular target: Phenylalanine.
- Target
- Phenylalanine
- Mechanism
- Phenylalanine hydrolytic enzyme
-
US regulatory status: approved. Molecular target: Phenylalanine.
- Target
- Phenylalanine
- Mechanism
- Phenylalanine hydrolytic enzyme
-
US regulatory status: approved. Molecular target: Peroxisome proliferator-activated receptor gamma.
- Target
- Peroxisome proliferator-activated receptor gamma
- Mechanism
- Peroxisome proliferator-activated receptor gamma agonist
-
Development asset linked to BioMarin Pharmaceutical Australia in public FDA and regional records.
-
Development asset linked to BioMarin Pharmaceutical Australia in public FDA and regional records.
-
Development asset linked to BioMarin Pharmaceutical Australia in public FDA and regional records.
-
Development asset linked to BioMarin Pharmaceutical Australia in public FDA and regional records.
-
sapropterin
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in BioMarin Pharmaceutical Australia's portfolio. Mechanism: Phenylalanine-4-hydroxylase activator.
- Mechanism
- Phenylalanine-4-hydroxylase activator
-
US regulatory status: approved. Molecular target: Phenylalanine-4-hydroxylase.
- Target
- Phenylalanine-4-hydroxylase
- Mechanism
- Phenylalanine-4-hydroxylase activator
-
Development asset linked to BioMarin Pharmaceutical Australia in public FDA and regional records.
-
Development asset linked to BioMarin Pharmaceutical Australia in public FDA and regional records.
-
Development asset linked to BioMarin Pharmaceutical Australia in public FDA and regional records.
-
Development asset linked to BioMarin Pharmaceutical Australia in public FDA and regional records.
-
talazoparib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in BioMarin Pharmaceutical Australia's portfolio. Molecular target: Poly [ADP-ribose] polymerase 2.
- Target
- Poly [ADP-ribose] polymerase 2
- Mechanism
- Poly [ADP-ribose] polymerase 2 inhibitor
-
US regulatory status: approved. Molecular target: Poly [ADP-ribose] polymerase 2.
- Target
- Poly [ADP-ribose] polymerase 2
- Mechanism
- Poly [ADP-ribose] polymerase-1 inhibitor
-
valoctocogene roxaparvovec
Blood and blood forming organs (B02)Blood and blood forming organs (B02) compound in BioMarin Pharmaceutical Australia's portfolio. Molecular target: Coagulation factor IX.
- Target
- Coagulation factor IX
- Mechanism
- Coagulation factor IX exogenous protein
-
vosoritide
Musculo-skeletal system (M05)US regulatory status: approved. Molecular target: Atrial natriuretic peptide receptor 2.
- Target
- Atrial natriuretic peptide receptor 2
- Mechanism
- Atrial natriuretic peptide receptor B binding agent